Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. - Sayed CJ; Kirby B; Garg A; Naik HB; Kimball AB; Zouboulis CC; Jemec GBE; Kokolakis G; Ingram JR; Morita A; Deherder D; Crater C; et al. (Journal of the American Academy of Dermatology, 2026)